JW Pharmaceutical Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 1,008.68 million compared to KRW 613.34 million a year ago. Net income was KRW 982.23 million compared to net loss of KRW 3,363.76 million a year ago. Basic earnings per share from continuing operations was KRW 35.9223 compared to basic loss per share from continuing operations of KRW 140.7767 a year ago. Basic earnings per share was KRW 35.9223 compared to basic loss per share of KRW 140.7767 a year ago.
For the six months, sales was KRW 2,396.73 million compared to KRW 3,555.79 million a year ago. Net income was KRW 10,566.26 million compared to KRW 668.43 million a year ago. Basic earnings per share from continuing operations was KRW 430.0971 compared to KRW 28.1553 a year ago. Basic earnings per share was KRW 430.0971 compared to KRW 28.1553 a year ago.